Anteris Technologies Announces First-Ever Patient Implanted in Global Pivotal PARADIGM Trial of DurAVR Bio-Inspired Heart Valve

May 06, 2026 08:00 CST Updated 08:00

Medtronic

Medical Device Manufacturer

Anteris touts first successful DurAVR valve-in-valve implant

The heart, as the "engine" of the human body, carries the hope of life with every beat. When the heart's "valve" — the aortic valve — becomes severely calcified and narrowed, it is equivalent to the engine's oil passage being blocked, posing an imminent risk of shutdown.

On May 5 (local time), a重磅消息 rocked the medical community: Anteris Technologies (NASDAQ: AVR), a biotech company from Australia, officially announced that its self-developed DurAVR heart valve had successfully completed the first patient implant in a global pivotal clinical trial! This marks not only an important milestone for Anteris but also holds promise to offer a new treatment option for patients worldwide suffering from severe calcific aortic stenosis.

Current Status of Treatment for Severe Calcified Aortic Stenosis

Here is a key point of knowledge for everyone: Severe calcified aortic stenosis is a fatal heart disease that severely limits the heart's pumping function. Patients often experience symptoms such as shortness of breath, chest pain, and fainting. In severe cases, it may lead to heart failure or even sudden death, and valve replacement is the only effective treatment.

In the past, the mainstream treatment for such patients was TAVR (Transcatheter Aortic Valve Replacement) — a minimally invasive technique that does not require open-heart surgery. Doctors deliver an artificial valve into the heart through a catheter to replace the function of the diseased valve, giving many elderly and high-risk patients who cannot tolerate open-heart surgery a new lease on life. However, there is still room for improvement in existing TAVR valves, and the DurAVR introduced by Anteris this time can be considered an "upgraded" bionic valve.

What's So Special About This "Bionic Valve"?

Anteris Technologies’ DurAVR heart valve tech featured at major medical ...

Unlike traditional artificial valves, DurAVR is a completely new bionic heart valve. It is also currently the world's only balloon-expandable, integrated transcatheter aortic valve—its design aim is to perfectly mimic the shape and function of the human native aortic valve, just like replacing the heart with an "original model" valve.

Even more impressive is its delivery method: using balloon expansion technology, it can precisely target the junction of the heart's native valve leaflets, achieving millimeter-level positioning, preventing valve displacement, and greatly enhancing surgical safety and postoperative outcomes. The precision of valve positioning directly determines the success of the surgery and the patient's postoperative recovery, making this one of the core technical advantages of DurAVR.

In fact, Anteris has long been strategically planning the development of this valve, with a clear timeline:

As early as 2023, Anteris successfully completed the first implantation of the DurAVR valve, preliminarily verifying the feasibility and safety of this bionic valve.

By the end of 2024, to further advance technology optimization and the implementation of clinical trials, the company launched an IPO to raise funds, injecting sufficient capital into its R&D efforts.

Earlier in 2026, medical giant Medtronic, recognizing the core technology potential of DurAVR, announced an investment of up to $90 million in Anteris, acquiring 16% to 19.99% of its equity. Through this powerful collaboration, they aim to advance the clinical trials and subsequent commercialization of this valve, progressively pushing this "bionic valve" from the laboratory to clinical practice.

Global Key Trial Launches, 1000 Patients to Benefit?

The first patient treatment was completed in Anteris's global pivotal PARADIGM trial. This is no ordinary clinical trial but a prospective, randomized controlled trial specifically targeting patients with severe calcified aortic valve stenosis, directly pitting DurAVR against currently approved mainstream TAVR valves in a "head-to-head competition."

According to the trial plan, the study will recruit approximately 1,000 patients worldwide, randomly assigned in a 1:1 ratio, with some patients receiving DurAVR treatment and others receiving conventional TAVR treatment. The primary objective of the trial is to demonstrate that DurAVR is non-inferior to existing mainstream products in key metrics such as all-cause mortality, stroke incidence, and cardiovascular hospitalization rates at 1 year post-surgery.

The first surgery of this kind was completed by Dr. Azeem Latib from Montefiore Medical Center in New York. As the principal investigator of the PARADIGM trial, Dr. Latib gave high praise to the performance of DurAVR:

The early surgical experience has been very encouraging. This trial not only focuses on conventional safety and hemodynamic indicators but also delves into the impact of blood flow patterns on left ventricular recovery, offering valuable insights for future patient treatment.

Giant Support + Technological Breakthrough: Is a Transformation of the Treatment Landscape on the Horizon?

For Anteris, the successful treatment of the first patient marks a critical step in the PARADIGM trial and signifies that DurAVR is another step closer to commercial implementation. Anteris CEO Wayne Paterson stated that, following approval from CMS (the Centers for Medicare & Medicaid Services), the team closely collaborated with physician partners and completed the recruitment and treatment of the first patient within a week. As research sites in the United States gradually come online, the capacity for patient recruitment will further increase.

要知道，心脏瓣膜治疗领域一直是医疗巨头的必争之地，美敦力的重磅投资，无疑为DurAVR的研发和推广注入了强大动力。作为全球领先的医疗技术公司，美敦力近年来持续布局结构性心脏领域，此次投资Anteris，正是看中了DurAVR的仿生技术优势，希望通过强强联合，巩固自身在TAVR领域的地位。

From a technical perspective, DurAVR’s integrated bionic design and precise positioning advantages are expected to address many of the pain points associated with existing TAVR valves. This is particularly beneficial for patients with complex anatomical structures or those who are difficult to fit with conventional valves, offering a safer and more effective treatment option. As the PARADIGM trial progresses, clinical data from 1,000 patients will further validate the efficacy and safety of this valve.

Every breakthrough in medical technology is aimed at protecting every heartbeat of life. For millions of patients worldwide with severe calcified aortic stenosis, the emergence of DurAVR may just be the beacon of hope to break through treatment barriers.

Going forward, we will continue to follow the progress of the PARADIGM trial, hoping that this "bionic heart valve" can successfully pass clinical trials and be commercialized as soon as possible, bringing new life to more patients!

Extended Tip: If you or someone around you is facing heart valve-related issues, it is recommended to consult a professional cardiologist promptly to learn about the latest treatment technologies and options. Do not make judgments on your own!